FINWIRES · TerminalLIVE
FINWIRES

調査速報:サザン・カンパニー第1四半期決算:卸売電気燃料部門、売上高・利益ともに予想を上回

By

-- 独立系調査会社CFRAは、に対し、以下の調査速報を提供しました。CFRAのアナリストは、以下のように見解をまとめています。サザン・カンパニーは、2026年第1四半期の調整後EPSが1.32ドルとなり、前年同期比7.3%増、ガイダンスを10.0%、市場予想を9.1%上回ったと発表しました。営業収益は8.0%増(市場予想比3.6%増)の84億ドルとなり、これは卸売電力収入が29.7%増の9億6,500万ドル、天然ガス収入が19.1%増の22億ドルとなったことによるものです。顧客数は前年同期比4万9,000人増加し、1.1%の成長を記録しました。天候調整後の小売売上高は2.3%増加し、商業部門(4.6%増)と産業部門(1.5%増)が好調でした。天候の影響により、実際の住宅向け販売が4.1%減少したため、四半期EPSは0.05ドル減少しました。サザン・パワーは大きな逆風に直面しており、風力発電施設の改修プロジェクトに伴う1億5400万ドルの加速償却費により、純利益は95.4%減の400万ドルに落ち込みました。さらに、2026年までに3億3500万ドル、2027年には1億ドルの追加費用が見込まれています。短期的にはサザン・パワーに課題があるものの、堅調な電力事業の業績と顧客数の増加傾向は、投資判断を裏付けるものと当社は考えています。

Related Articles

Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of Firstenergy Corp.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target by $1 to $55, 20.0x our next-12-month EPS view of $2.75, a premium to its five-year average of 15.6x. We reduce our 2026 EPS view by $0.02 to $2.72 and 2027 EPS by $0.01 to $2.93. The Q1 core EPS increase (+7.5% Y/Y) breaks a three-quarter streak of declines, and we see continued momentum throughout our forecast horizon. We see positive data center demand trends, with long-term contracted demand (4.3 GW) up 4% since February 2026 (4.1 GW) and up 47% since February 2025 (2.9 GW), while pipeline demand (14.9 GW) is up 15% since February 2026 (12.9 GW) and has more than doubled since February 2025 (6.1 GW). FE has reduced base O&M by over $200M (15%) since 2022, with Q1 2026 showing an additional ~5% YoY decline, while simultaneously improving reliability metrics. We think FE's cost discipline, service quality improvement, and competitive rate positioning should translate into more favorable rate case outcomes, reduced disallowance risk, and potentially higher allowed ROEs.

$FE
Sectors

Sector Update: Consumer

Consumer stocks were higher Thursday afternoon, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) rising 1.4% and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) increasing 0.4%.In corporate news, Lamb Weston (LW) shares rose 1.6% after shareholder Starboard Value said in a letter to the board Thursday that the company should hold an investor day and reset earnings to a normalized level.

$LW
Australia

Market Chatter: FDA Panel Votes Against Benefits of AstraZeneca's Breast Cancer Drug

The US Food and Drug Administration's Oncology Drugs Advisory Committee rejected the benefits AstraZeneca's (AZN) Camizestrant drug candidate to treat breast cancer, Bloomberg reported Thursday.Six committee members voted against the drug due to disagreement over the trial design and the potential implications in the clinical setting, according to Bloomberg.The drug trial met is primary endpoint of progression-free survival as well as the progression-free survival 2 endpoint, however, FDA does not consider PFS2 a suitable endpoint for regulatory decision making, according to a briefing document.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $189.60, Change: $+4.40, Percent Change: +2.37%

$AZN